EDIL3/DEL1 Antibody (670421) [Alexa Fluor® 700]

• Reactivity: Hu
• Applications: WB
• Clone: 670421
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Alexa Fluor 700

EDIL3/DEL1 Antibody (670421) [Alexa Fluor® 700] Summary

• Immunogen: Chinese hamster ovary cell line CHO-derived recombinant human EDIL3
  Val17-Glu480
  Accession # O43854
• Specificity: Detects human EDIL3 in direct ELISAs and Western blots. In direct ELISAs, no cross-reactivity with recombinant human MGF-E8 is observed.
• Isotype: IgG2a
• Clonality: Monoclonal
• Host: Mouse
• Purity Statement: Protein A or G purified

Applications/Dilutions

• Dilutions:
  • Western Blot

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for EDIL3/DEL1 Antibody (670421) [Alexa Fluor® 700]

• DEL1
• DEL1developmental endothelial locus-1
• Developmentally-regulated endothelial cell locus 1 protein
• EDIL3
• EGF-like repeat and discoidin I-like domain-containing protein 3
• EGF-like repeats and discoidin I-like domains 3
• Integrin-binding protein DEL1
• MGC26287

Background

EGF-like repeat and discoidin I-like domain-containing protein 3 (EDIL3; also Del-1 and integrin-binding DEL1) is a 52 kDa extracellular matrix protein that is expressed by endothelial tissues during embryonic vascular development (1). Human EDIL3 is synthesized as a precursor with a 16 amino acid (aa) signal sequence and a 464 aa mature chain. The mature chain is composed of three epidermal growth factor (EGF) repeats and two discoidin-I-like domains (1). The second EGF repeat contains an RGD motif (1). Splicing variants produce two isoforms for human EDIL3. Isoform 2 has an A->G substitution at aa 66 and a deletion of aa 67-76 found in isoform 1. Mature human EDIL3 shares 96% aa sequence identity with mature mouse EDIL3. The RGD motif of EDIL3 binds alpha v beta 5 integrin, which, in turn, leads to increased angiogenic transcription factor HoxD3 expression (2). HoxD3activates alpha v beta 3 and uPA, resulting in the transformation of resting endothelial cells to an angiogenic state (2-4). EDIL3 becomes quiescent at the time of birth, and is no longer expressed in normal adult tissues. It has been found, however, re-expressed in a number of human tumors as well as in ischemic muscles and ischemic brain tissue, which may play an important role in adult angiogenesis (2, 5-6). EDIL3 promotes adherence and migration of endothelial cells, and acts as an endothelial cell survival agent through upregulation of Bcl-2 expression (7). Exogenous application of EDIL3 has been demonstrated to augment angiogenesis and improve blood flow and tissue function in murine models of hind-limb ischemia (6, 8), cardiac ischemia (9) and cerebral ischemia (2). EDIL3 has also been shown to be an endogenous inhibitor of inflammatory cell recruitment by interfering with the integrin LFA-1-dependent leukocyte-endothelial adhesion (10).

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.